Back to School: How biopharma can reboot drug development. Access exclusive analysis here

A softening

Biotech's strong run since the beginning of the year has hit some potholes, with last week's 5 percent fall in the BioCentury 100 Price Level index the third downtick in the past four weeks

When the BioCentury 100 peaked on Feb. 14 at 1337.17, it was up an impressive 11.5 percent on the year, compared with a 5.9 percent gain in the NASDAQ Composite, an 8.4 percent gain in the Dow Jones Industrials, and a 9.1 percent gain in the S&P 500. The 190 companies in the Carson Life Sciences Index of smaller cap companies (<$500 million) gained $3.5 billion in aggregate market capitalization (15.6 percent) in the year to Feb. 14, while the Large Cap group had added $700 million (2.3 percent).

As of last Friday, the BioCentury 100 is up only 2.7 percent on the year.

The optimists will attribute the sales to "profit-taking" that won't be long-lived. "It's a short-term phenomenon," said Matt Kaplan, senior analyst at The Carson Group, "We're seeing some momentum and aggressive growth funds getting skittish over the price appreciation over the last few months."

If, however, the downturn

Read the full 1870 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE